image credit- shutterstock
Roche has announced plans to invest up to $550 million in its Diagnostics site in Indianapolis, US by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.
Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group.
"The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires," said Brad Moore, President and CEO of Roche Diagnostics North America. "By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the US and worldwide."
The Indianapolis campus houses key operations, including US research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as one of two global distribution hubs focused on serving the US market and supporting distribution to 53 countries worldwide.
Building on more than $800 million in US investments made at Roche US sites since 2015, this new commitment reinforces Roche's longterm dedication to US operations and highlights the country's central role in the company's global strategy.
The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana's economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing.
